NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines

NICE says evidence that COVID-19 treatment Evusheld is effective in protecting vulnerable adults against current variants is lacking as it announces new rapid update process for COVID-19 medicines The National Institute for Health and Care Excellence has issued draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in adults who are unlikely to have an adequate immune response to COVID-19 vaccination, or who can’t be vaccinated.

See also:

• Tixagevimab plus cilgavimab for preventing COVID-19 (draft guidance) NICE
• Evusheld European Medicines Agency
• Covid-19: Evusheld is unlikely to prevent infection with current or future variants, NICE concludes The BMJ
• AstraZeneca sends updated Covid drug Evusheld to regulators for approval The Daily Mail
• U.S. FDA pulls authorization for AstraZeneca's COVID-19 treatment Evusheld Reuters